Your browser doesn't support javascript.
A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations.
Grzelak, Ludivine; Temmam, Sarah; Planchais, Cyril; Demeret, Caroline; Tondeur, Laura; Huon, Christèle; Guivel-Benhassine, Florence; Staropoli, Isabelle; Chazal, Maxime; Dufloo, Jeremy; Planas, Delphine; Buchrieser, Julian; Rajah, Maaran Michael; Robinot, Remy; Porrot, Françoise; Albert, Mélanie; Chen, Kuang-Yu; Crescenzo-Chaigne, Bernadette; Donati, Flora; Anna, François; Souque, Philippe; Gransagne, Marion; Bellalou, Jacques; Nowakowski, Mireille; Backovic, Marija; Bouadma, Lila; Le Fevre, Lucie; Le Hingrat, Quentin; Descamps, Diane; Pourbaix, Annabelle; Laouénan, Cédric; Ghosn, Jade; Yazdanpanah, Yazdan; Besombes, Camille; Jolly, Nathalie; Pellerin-Fernandes, Sandrine; Cheny, Olivia; Ungeheuer, Marie-Noëlle; Mellon, Guillaume; Morel, Pascal; Rolland, Simon; Rey, Felix A; Behillil, Sylvie; Enouf, Vincent; Lemaitre, Audrey; Créach, Marie-Aude; Petres, Stephane; Escriou, Nicolas; Charneau, Pierre; Fontanet, Arnaud.
  • Grzelak L; Virus and Immunity Unit, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France.
  • Temmam S; Vaccine Research Institute, Creteil, France.
  • Planchais C; Université de Paris, Sorbonne Paris Cité, Paris, France.
  • Demeret C; Pathogen Discovery Laboratory, Department of Virology, Institut Pasteur, Paris, France.
  • Tondeur L; Laboratory of Humoral Immunology, Department of Immunology, Institut Pasteur, INSERM U1222, Paris, France.
  • Huon C; Molecular Genetics of RNA Viruses, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France.
  • Guivel-Benhassine F; Université de Paris, Paris, France.
  • Staropoli I; Emerging Diseases Epidemiology Unit, Department of Global Health, Institut Pasteur, Paris, France.
  • Chazal M; Pathogen Discovery Laboratory, Department of Virology, Institut Pasteur, Paris, France.
  • Dufloo J; Virus and Immunity Unit, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France.
  • Planas D; Vaccine Research Institute, Creteil, France.
  • Buchrieser J; Virus and Immunity Unit, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France.
  • Rajah MM; Vaccine Research Institute, Creteil, France.
  • Robinot R; Department of Virology, Institut Pasteur, Paris, France.
  • Porrot F; Virus and Immunity Unit, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France.
  • Albert M; Vaccine Research Institute, Creteil, France.
  • Chen KY; Université de Paris, Sorbonne Paris Cité, Paris, France.
  • Crescenzo-Chaigne B; Virus and Immunity Unit, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France.
  • Donati F; Vaccine Research Institute, Creteil, France.
  • Anna F; Virus and Immunity Unit, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France.
  • Souque P; Vaccine Research Institute, Creteil, France.
  • Gransagne M; Virus and Immunity Unit, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France.
  • Bellalou J; Vaccine Research Institute, Creteil, France.
  • Nowakowski M; Université de Paris, Sorbonne Paris Cité, Paris, France.
  • Backovic M; Virus and Immunity Unit, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France.
  • Bouadma L; Vaccine Research Institute, Creteil, France.
  • Le Fevre L; Virus and Immunity Unit, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France.
  • Le Hingrat Q; Vaccine Research Institute, Creteil, France.
  • Descamps D; Molecular Genetics of RNA Viruses, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France.
  • Pourbaix A; Université de Paris, Paris, France.
  • Laouénan C; National Reference Center for Respiratory Viruses, Institut Pasteur, Paris, France.
  • Ghosn J; RNA Biology of Influenza Virus, Department of Virology, Institut Pasteur, Paris, France.
  • Yazdanpanah Y; Molecular Genetics of RNA Viruses, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France.
  • Besombes C; Université de Paris, Paris, France.
  • Jolly N; Molecular Genetics of RNA Viruses, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France.
  • Pellerin-Fernandes S; Université de Paris, Paris, France.
  • Cheny O; National Reference Center for Respiratory Viruses, Institut Pasteur, Paris, France.
  • Ungeheuer MN; Pasteur-TheraVectys joined unit, Institut Pasteur, Paris, France.
  • Mellon G; Molecular Virology and Vaccinology Unit, Department of Virology, Institut Pasteur, Paris, France.
  • Morel P; Innovation lab: Vaccines, Institut Pasteur, Paris, France.
  • Rolland S; Plate-Forme Technologique Production et Purification de Protéines Recombinantes, Institut Pasteur, Paris, France.
  • Rey FA; Plate-Forme Technologique Production et Purification de Protéines Recombinantes, Institut Pasteur, Paris, France.
  • Behillil S; Structural Virology Unit, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France.
  • Enouf V; Université of Paris, INSERM UMR 1137 IAME, Paris, France.
  • Lemaitre A; Medical and Infectious Diseases Intensive Care Unit, Assistance Publique-Hôpitaux de Paris, Bichat-Claude-Bernard University Hospital, Paris, France.
  • Créach MA; Medical and Infectious Diseases Intensive Care Unit, Assistance Publique-Hôpitaux de Paris, Bichat-Claude-Bernard University Hospital, Paris, France.
  • Petres S; Université of Paris, INSERM UMR 1137 IAME, Paris, France.
  • Escriou N; Department of Virology, Assistance Publique-Hôpitaux de Paris, Bichat-Claude-Bernard University Hospital, Paris, France.
  • Charneau P; Université of Paris, INSERM UMR 1137 IAME, Paris, France.
  • Fontanet A; Department of Virology, Assistance Publique-Hôpitaux de Paris, Bichat-Claude-Bernard University Hospital, Paris, France.
Sci Transl Med ; 12(559)2020 09 02.
Article in English | MEDLINE | ID: covidwho-724557
Semantic information from SemMedBD (by NLM)
1. Specimen Type - Serum PART_OF Homo sapiens
Subject
Specimen Type - Serum
Predicate
PART_OF
Object
Homo sapiens
2. Assay DIAGNOSES 2019 novel coronavirus
Subject
Assay
Predicate
DIAGNOSES
Object
2019 novel coronavirus
3. Specimen Type - Serum LOCATION_OF Anti-Antibodies
Subject
Specimen Type - Serum
Predicate
LOCATION_OF
Object
Anti-Antibodies
4. Anti-Antibodies PART_OF 2019 novel coronavirus
Subject
Anti-Antibodies
Predicate
PART_OF
Object
2019 novel coronavirus
5. Antigens PART_OF 2019 novel coronavirus
Subject
Antigens
Predicate
PART_OF
Object
2019 novel coronavirus
6. Immunoprecipitation USES Luciferases
Subject
Immunoprecipitation
Predicate
USES
Object
Luciferases
7. Immunoprecipitation METHOD_OF Flow Cytometry
Subject
Immunoprecipitation
Predicate
METHOD_OF
Object
Flow Cytometry
8. Cell surface LOCATION_OF Vitronecti
Subject
Cell surface
Predicate
LOCATION_OF
Object
Vitronecti
9. COVID-19 PROCESS_OF hospitalized patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
hospitalized patients
10. Assay USES Antibodies
Subject
Assay
Predicate
USES
Object
Antibodies
11. Evaluation TREATS Population Group
Subject
Evaluation
Predicate
TREATS
Object
Population Group
12. Specimen Type - Serum PART_OF Homo sapiens
Subject
Specimen Type - Serum
Predicate
PART_OF
Object
Homo sapiens
13. Assay DIAGNOSES 2019 novel coronavirus
Subject
Assay
Predicate
DIAGNOSES
Object
2019 novel coronavirus
14. Specimen Type - Serum LOCATION_OF Anti-Antibodies
Subject
Specimen Type - Serum
Predicate
LOCATION_OF
Object
Anti-Antibodies
15. Anti-Antibodies PART_OF 2019 novel coronavirus
Subject
Anti-Antibodies
Predicate
PART_OF
Object
2019 novel coronavirus
16. Antigens PART_OF 2019 novel coronavirus
Subject
Antigens
Predicate
PART_OF
Object
2019 novel coronavirus
17. Immunoprecipitation USES Luciferases
Subject
Immunoprecipitation
Predicate
USES
Object
Luciferases
18. Immunoprecipitation METHOD_OF Flow Cytometry
Subject
Immunoprecipitation
Predicate
METHOD_OF
Object
Flow Cytometry
19. Cell surface LOCATION_OF Vitronectin, human
Subject
Cell surface
Predicate
LOCATION_OF
Object
Vitronectin, human
20. COVID-19 PROCESS_OF hospitalized patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
hospitalized patients
21. Assay USES Antibodies
Subject
Assay
Predicate
USES
Object
Antibodies
22. Evaluation TREATS Population Group
Subject
Evaluation
Predicate
TREATS
Object
Population Group
ABSTRACT
It is of paramount importance to evaluate the prevalence of both asymptomatic and symptomatic cases of SARS-CoV-2 infection and their differing antibody response profiles. Here, we performed a pilot study of four serological assays to assess the amounts of anti-SARS-CoV-2 antibodies in serum samples obtained from 491 healthy individuals before the SARS-CoV-2 pandemic, 51 individuals hospitalized with COVID-19, 209 suspected cases of COVID-19 with mild symptoms, and 200 healthy blood donors. We used two ELISA assays that recognized the full-length nucleoprotein (N) or trimeric spike (S) protein ectodomain of SARS-CoV-2. In addition, we developed the S-Flow assay that recognized the S protein expressed at the cell surface using flow cytometry, and the luciferase immunoprecipitation system (LIPS) assay that recognized diverse SARS-CoV-2 antigens including the S1 domain and the carboxyl-terminal domain of N by immunoprecipitation. We obtained similar results with the four serological assays. Differences in sensitivity were attributed to the technique and the antigen used. High anti-SARS-CoV-2 antibody titers were associated with neutralization activity, which was assessed using infectious SARS-CoV-2 or lentiviral-S pseudotype virus. In hospitalized patients with COVID-19, seroconversion and virus neutralization occurred between 5 and 14 days after symptom onset, confirming previous studies. Seropositivity was detected in 32% of mildly symptomatic individuals within 15 days of symptom onset and in 3% of healthy blood donors. The four antibody assays that we used enabled a broad evaluation of SARS-CoV-2 seroprevalence and antibody profiling in different subpopulations within one region.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Document Type: Article Main subject: Pneumonia, Viral / Serologic Tests / Coronavirus Infections / Clinical Laboratory Techniques / Betacoronavirus / Antibodies, Viral Subject: Pneumonia, Viral / Serologic Tests / Coronavirus Infections / Clinical Laboratory Techniques / Betacoronavirus / Antibodies, Viral Type of study: Diagnostic study / Etiology study / Incidence study / Observational study / Risk factors Language: English Clinical aspect: Diagnosis / Etiology Year: 2020

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Document Type: Article Main subject: Pneumonia, Viral / Serologic Tests / Coronavirus Infections / Clinical Laboratory Techniques / Betacoronavirus / Antibodies, Viral Subject: Pneumonia, Viral / Serologic Tests / Coronavirus Infections / Clinical Laboratory Techniques / Betacoronavirus / Antibodies, Viral Type of study: Diagnostic study / Etiology study / Incidence study / Observational study / Risk factors Language: English Clinical aspect: Diagnosis / Etiology Year: 2020
...